Stay updated on Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check63 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check77 days agoChange DetectedThe webpage has been updated to reflect a new version of a clinical study on metastatic breast cancer, including a change in the principal investigator and the addition of specific treatment details. The study now emphasizes the use of Pembrolizumab in combination with HER2 Bispecific Antibody Armed Activated T-Cell infusions.SummaryDifference45%
- Check84 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.